Table 2.
Treatment history one year prior to index date
| Cancer treatments one year prior to index date | Overall | Patients who received CDK4/6 inhibitors + AI | Patients who received CDK4/6 inhibitors + fulvestrant |
|---|---|---|---|
| (N = 6061) | (N = 4032) | (N = 2029) | |
| Any cancer medication, N (%) | 3370 (55.6) | 1668 (41.4) | 1702 (83.9) |
| AI, N (%) | 2659 (43.9) | 1192 (29.6) | 1467 (72.3) |
| Tamoxifen, N (%) | 687 (11.3) | 462 (11.5) | 225 (11.1) |
| Chemotherapy N (%) | 554 (9.1) | 274 (6.7) | 280 (13.8) |
| Radiotherapy | 148 (2.4) | 81 (2.0) | 67 (3.3) |
| Surgery, N (%) | 407 (6.7) | 331 (8.2) | 76 (3.8) |
| No evidence of AI or tamoxifen (proxy for endocrine sensitivity) | 2899 (47.8) | 2490 (61.8) | 409 (20.2) |